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Heart disease, including valve pathologies, is the leading cause of death worldwide. Despite 
the progress made thanks to improving transplantation techniques, a perfect valve substitute 
has not yet been developed: once a diseased valve is replaced with current technologies, the 
newly implanted valve still needs to be changed some time in the future. This situation is 
particularly dramatic in the case of children and young adults, due to the necessity of valve 
growth during the patient’s life. Our review focuses on the current status of heart valve 
therapy and the challenges that must be solved in the development of new approaches based 
on tissue engineering. Scientists and physicians have proposed tissue-engineered heart 
valves (TEHVs) as the most promising solution for heart valve replacement, especially 
given that they can help to avoid thrombosis, structural deterioration, and xenoinfections. 
Lastly, TEHVs might also serve as a model for studying human valve development and 
pathologies. 
* Corresponding author: carmen.escobedo-lucea@helsinki.fi  
 
1. Introduction 
Cardiovascular diseases, including severe cardiac 
valve disorders, are the leading global cause of 
disability and death, causing more than 17.5 
million deaths a year (Ref. 1); the prevalence of 
valvular heart disease in the United States of 
America (USA) is estimated at more than 5 million 
people. Moreover, aortic valve disease, which 
affects 2.5% of the US adult population to some 
extent, is responsible for more than 25,000 deaths 
each year (Ref. 2). Also, 3% of sudden deaths in 
the European Union (EU) are caused by cardiac 
valve defects. Over the preceding decades valvular 
heart diseases were not considered a major public 
health problem. However, Nkomo et al. (Ref. 3) 
demonstrated in 2006 that the high prevalence of 
these disorders, together with their boost with 
ageing, indicated the burden of these conditions 
would only likely increase in the future. 
The advent of organ transplantation has brought 
about the greatest progress in cardiac valve disease 
treatment so far, however, the number of patients 
that need heart valve replacements is rising by an 
average of 5% per year (Ref. 4). This number is 
likely to triple over the next five decades due to the 
continuously increasing aging of the population in 
developed countries (Ref. 5). According to the 
Global Alliance in Transplantation, the USA is 
currently the world’s leader in heart valve 
replacements, reaching 95,000 cases per year (Ref. 
6) but this is not an exception. By the year 2020, 
20.2% of EU population will be older than 65. The 
growing pool of older people living in the area with 
age related heart valve disorders will continue to 
boost demand for heart valve repair and 
replacement procedures. These medical procedures, 
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only in EU countries, generated $827.5 million 
expenses in 2010, and the estimate for 2015 is to 
reach $1,375.3 million (Ref. 7). 
Even more dramatic is the case of children and 
young adults where cardiac valve defects represent 
approximately 30% of all congenital cardiovascular 
malformations. Only in the USA, the incidence is 
estimated at 1-2/1,000 births, and globally is 
around 8/1,000 births (Ref. 8, 9). Congenital heart 
defects are relatively common and serious 
malformations having significant impact on 
morbidity, mortality, and healthcare costs. 
Homografts are used for their long durability in 
these patients but they show a higher 
immunological response compared to adults (Ref. 
10). Moreover post-surgical calcification and the 
ultimate destruction of the valve replacement 
always occur more frequently in children and 
young adults than in old patients. In addition, the 
durability of the homografts in this case is also 
limited because of their inability to grow with 
concomitant growth of child organism. 
Consequently, the need for reoperation is higher in 
younger patients (O'Brien, 2001 #898;Rajani, 1998 
#897}. Further efforts focused on paediatric 
recipients of cardiac valves are required. 
Although organ replacement saves many lives the 
need for more donors, together with the collateral 
problems caused after transplantation, encourage 
the search for new alternatives (Ref. 11, 12). 
Cardiac valve replacement is not an exception to 
the rule and several problems have to be solved: the 
administration of lifelong immunosuppressive 
drugs, poor durability and resulting short lifespan 
of the mechanical prostheses, structural degradation 
of the biological valve replacement, risk of 
rejection, and the risk of zoonosis from 
xenotransplants. Even with the significant 
innovations currently reached, a perfect valve 
substitute has still not yet been developed (Ref. 11), 
and approaches based on tissue engineering (TE) 
are now being considered for developing artificial 
heart valves (Ref. 13, 14). 
Tissue-engineered heart valves (TEHVs) have the 
potential to become the best solution for treating 
valvular heart diseases due to their non-
thrombogenicity, decreased risk of infections and 
low structural deterioration over time (Ref. 
13).There are two crucial challenges derived from 
three major components (cells, scaffolds and 
signalling molecules) in TE field; the former is the 
selection of potential candidate cell types and their 
related issues concerning ethics, safety, and 
effectiveness. The latter is the design of appropriate 
scaffolds that let for cell growth and differentiation 
as well as host tissue integration. 
In this review we evaluate the current treatment 
strategies for valvular heart disease and their 
limitations with a view to provide valuable 
information in selecting the best approach for heart 
valve tissue engineering (HVTE), the challenges 
that HVTE faces today and the current status of the 
research in the field. This review focuses on the 
aortic valve due to the fact that aortic diseases have 
the poorest prognosis, even the higher incidence of 
mitral valve diseases in the population (Ref. 15). 
However, research on pulmonary valve is also 
taken into account since pulmonary autograft 
represents a proof of principle for clinical 
effectiveness of TEHVs (Ref. 16, 17). 
2. Understanding of heart valve 
biology 
2.1. Substructural elements 
Mammalian hearts comprise four heart valves: 
pulmonary, aortic, mitral, and tricuspid, whose 
primary function is to maintain a unidirectional 
blood flow during the cardiac cycle. We focus in 
the first two types, which are shown in Figure 1a 
and 1b, but especially our main interest is the aortic 
valve. Pulmonary and aortic valves, also called 
semilunar valves, are commonly affected by 
pathological processes, but with distinct 
mechanisms of failure (Ref. 18) that we will treat 
later. Both share similar structure containing three 
semicircular leaflets, or cusps, joined to a fibrous 
annulus called the root. According to Stradins et al. 
(Ref. 19), aortic and pulmonary valve tissues have 
similar mechanical characteristics and composition, 
but exhibit slight differences in their layer density 
and thickness. The cross-sectional structure of the 
leaflets is divided into three layers, namely the 
ventricularis, spongiosa, and fibrosa (Ref. 12) 
whose structure and composition are detailed in the 
cross-sectional diagram in Figure 2. These layers 
are dynamic tissues with complex structure mainly 
composed of valvular interstitial cells (VICs) and 
endothelial cells (VECs) combined with 
extracellular matrix (ECM). This make them 
capable of remodelling themselves in response to 
the changes generated by local forces (Ref. 20). 
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The semilunar valves also possess blood vessels. 
The majority of them are present in the proximal 
portion near the myocardium, with few found in the 
cusps, which are nourished by diffusion from the 
blood in the heart because of their thinner structure. 
The creation of a functional TEHV requires 
profound knowledge of the healthy valve structure, 
the biological processes associated with their 
development, and also their functional features and 
requirements for their formation. The main 
components that comprised the aortic valve are 
described in the following subsections. 
2.2.1. Valvular interstitial cells 
Valvular interstitial cells, the most abundant cell 
type in heart valves, are a heterogeneous population 
embedded in their own ECM. Liu et al. (Ref. 21) 
classified these cells in five different types: 
embryonic endothelial progenitor cells (EPCs) 
(Ref. 22), quiescent (Ref. 23), activated (Ref. 24, 
25), progenitor (Ref. 26, 27, 28), and osteoblastic 
VICs (Ref. 29). They have particular characteristics 
and functions regulated by environmental 
conditions that are summarized in Table 1. VICs 
properties are also different in health and disease. 
For example VICs from aortic and mitral valve are 
stiffer than those from pulmonary and tricuspid, 
suggesting that VICs respond to local tissue stress 
by altering their stiffness (Ref. 30). 
From the morphological point of view VICs have a 
fusiform and fibroblastic shape with prominent 
cytoplasmic extensions and an incomplete basal 
lamina (Ref. 31, 32). They are mainly characterised 
by their cytoplasm, which is rich in mitochondria, 
rough endoplasmic reticulum, and frequently 
exocytic vesicles (Ref. 33). VICs mediate matrix 
remodelling and also maintain valve homeostasis. 
They are crucial for supporting normal valve 
physiology, playing an important role in some 
pathological valve processes (Ref. 34). 
2.2.2. Valvular endothelial cells 
Valvular endothelial cells (VECs) are in charge of 
maintaining a non-thrombogenic surface, nutrient 
transport, and transduction of biochemical and 
mechanical signals in the heart valve. They are 
located in parallel to the ECM collagen fibres of 
valves and perpendicular to the blood flow 
direction (Ref. 35). VECs release factors that act on 
the underlying VICs, inhibiting their proliferation 
and increasing ECM synthesis (Ref. 36). They 
share some similarities with vascular endothelial 
cells. They present cobblestone-like morphology 
when cultured in vitro and also exhibit contact 
inhibition. Preliminary studies indicated that 
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subpopulations of these cells were also able to 
transdifferentiate into smooth muscle–like 
phenotype (Ref. 35). Moreover, VECs dysfunction 
seems to be involved in certain cardiovascular 
diseases (Ref. 37).  
2.2.3. Extracellular matrix 
The ECM is considered to be the main responsible 
for the durability of heart valves. As shown in 
Figure 2, its principal components are collagens 
type I and type III, elastin, glycosaminoglycans 
(GAGs), and proteoglycans (PGs). Collagens are 
fundamental for valve´s biomechanical functions, 
providing stiffness and elasticity; moreover, they 
have a strong influence on cell adhesion and 
migration (Ref. 38). Microscopically, the three 
layers that make up the valve have different ECM 
composition. For instance the thinnest layer, the 
ventricularis, is mainly composed of elastin which 
provides elasticity (Ref. 39), whereas the thickest 
layer, the fibrosa that is in charge of providing 
mechanical strength and load resistance to the 
valve, mainly contains collagen I and III (3:1) and 
2% of collagen type IV (Ref. 33, 40).  
The spongiosa layer, responsible for the 
compressible stiffness required for proper heart 
valve function, contains mainly GAGs and PGs. 
GAGs are largely responsible for the huge water-
absorbing capacity of this layer thanks to the high 
concentration of negative charges that they carry. 
Furthermore, GAGs are also required for hydration 
of the spongiosa layer and absorb compressive 
forces, reducing flexural deformation (Ref. 41). 
Given their nature, GAGs can also reduce the 
calcification process by chelating calcium ions. All 
of these features are important factors which go 
towards explaining the mechanical behaviour of 
heart valve tissues. In particular GAGs are crucial 
components that must be considered when creating 
TEHVs. For instance, after the process of 
decellularization with detergents, GAG loss was 
observed in valve tissues, compromising their 
structure and functions (Ref. 42). 
Heart valve ECM is subjected to dynamic 
remodelling, which is induced by VICs. The 
quantity and quality of ECM essentially depends on 
the nature of the VICs (Ref. 33, 40). The 
relationship between ECM organisation and VIC 
distribution is also crucial during development and 
in pathological states (Ref. 33). Walker et al. (Ref. 
43) observed that various genes associated with 
ECM are mutated in congenital valve diseases, 
highlighting its importance in the morphology and 
functionality of heart valves. 
2.3. Heart valve biomechanics and 
related illnesses 
Mitral and aortic valves are in charge of pumping 
the blood, experiencing intense pressure, and 
supporting higher biomechanical stress than 
pulmonary and tricuspid. Therefore, they are more 
affected by pathologies and degenerative processes 
while alterations in pulmonary or tricuspid valves 
are less common and mainly related with genetic or 
foetal defects (Ref. 12). Valve pathologies are 
characterized within two functional groups: 
stenosis and regurgitation. Haemodinamically, the 
pulmonary valve flow profile is similar to that of 
the aortic, but the velocity magnitude is lower (Ref. 
30). The slightly difference in the biomechanical 
and ultrastructural properties aforementioned in 
Section 2.1 strongly constraints the type of disease 
developed. Pathologies of the aortic valve can be 
triggered by inflammation or by degenerative valve 
disease, caused by aging coupled with rheumatic 
and infective endocarditis (Ref. 44). On the 
contrary, congenital stenosis is the most common 
pulmonary valve pathology, mainly caused by a 
defect during foetal development; this alteration is 
normally solved by surgery during infancy. Finally, 
mitral regurgitation, which can be caused by 
rheumatic fever, congenital abnormalities, ischemic 
heart disease or cardiomyopathies, is the most 
common functional abnormality of this valve. 
3. Cardiac valve problems and 
clinical strategies for their 
treatment: the importance of 
valve tissue banks. 
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As we mentioned above, different illnesses can 
compromise and damage the delicate structure of 
heart valves, triggering their alteration and causing 
the three main valve problems: regurgitation, 
stenosis and calcification. In the past the 
inflammation caused by rheumatic heart disease 
and endocarditis induced by bacterial infections 
were the root causes of valve alterations. Although 
these problems remain a major health roadblock in 
developing countries (Ref. 3), valve dysfunctions in 
the industrialized world are almost always caused 
by degenerative diseases, mostly as a result of 
aging and congenital defects (Ref. 11). Several 
drugs can be used as short-term therapies to 
improve the health and condition of patients with 
severe valvular pathologies, however in most cases 
the best option for correcting the problem is to 
proceed with valve repair surgery and/or 
replacement. The choice of surgical procedure is 
adapted to the team’s experience, the presence of 
an aneurysm, the characteristics of the leaflets, and 
also to the patient’s condition and life expectancy 
(Ref. 11). 
Current alternatives for HV replacements are 
mechanical and biological (xenogeneic and 
allogeneic) implants (strategy A in Figure 3). 
3.1. Mechanical implants 
Since 1960, when Harken (Ref. 45) and Starr (Ref. 
46) reported the first successful surgical 
implantations of a mechanical heart valve, their use 
has widespread and they are now the option 
selected in more than 50% of replacement 
surgeries. The main advantage is their high 
mechanical strength; but although mechanical 
implants are very resistant and work satisfactorily 
for years, they carry with them the risk of 
thrombosis generated by high shear stress, blood 
alterations or non-physiological flows (Ref. 47). 
Consequently, they generally imply the use of 
anticoagulant medication for the rest of the 
patient’s life (Ref. 48). 
3.2. Bioprosthetic valves  
The bioprosthetic valves can be obtained from 
animal (xenografts) or human origin (autografts 
and allografts/ homografts). Compared with their 
mechanical counterparts, bioprostheses are affected 
by structural dysfunction due to tissue 
degeneration, so they need to be replaced within 
10-15 years. For this reason current clinical 
guidelines recommend the use of bioprosthetic 
replacements in patients over 65 years (Ref. 15, 
47). 
Xenografts have usually bovine or porcine origin. 
Once extracted, they are fixed with glutaraldehyde 
(GA) to prevent rejection (by masking 
immunogenic epitopes) and zoonosis (Ref. 49). 
Animal valves do not induce clot formation but 
they entail a risk of xenoinfection and degrade 
faster (Ref. 50, 51). Their dysfunction is motivated 
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due to tissue damage, mainly by calcification and 
collagen degradation.  
Those detrimental processes seem to be triggered 
by the use of GA during fixation. Fixation with GA 
preserves the integrity of membrane phospholipids, 
which remain in the valve after the treatment. 
These lipids react with the surrounding 
extracellular calcium, creating aggregates and 
promoting valve calcification. Because calcification 
evolves faster in young patients, xenogeneic 
replacements are mainly prescribed in patients with 
high death risk or advanced age (Ref. 
51).Moreover, GA degrades animal´s VICs and 
VECs of valves, affecting also to the collagen 
matrix and destroying the functional structure. 
Once implanted, the receptor’s cells are not able to 
restore the functionality, and they start to secrete 
altered ECM proteins profile, increasing the 
damage (Ref. 50). Several alternatives to solve this 
problem have been tried however, without great 
success (Ref. 52, 53). 
Given their better hemodynamic profile, human 
allografts, or autografts in the case of Ross 
procedure, are currently the optimal solution, but 
due to their  importance and peculiarities,  they 
deserve a detailed study(Ref. 54).  
3.1. Human homografts and the 
importance of heart valve tissue 
banking 
Since the last century, thousands of heart valve 
homografts (especially aortic and pulmonary) have 
been used in reconstructive cardiac surgery and 
tissue replacement (Ref. 16, 44, 55, 56). One of the 
main differences between cardiac valve homografts 
and other tissues for transplantation (e.g. bone) is 
that the valve conduits need to perform at its best 
immediately after surgery. Additionally, the clinical 
outcome of an homograft can be conditioned by the 
physiologic process of inflammation, the 
biomechanical stress, the immune response and 
other molecular events. 
Once the tissue has been transplanted, the analysis 
of factors which could play a significant role in its 
deterioration also remains as controversial issue. 
Cell viability is one of the most controversial topics 
at this point. Several authors have reported that 
maintaining the viability of cells residing within the 
graft have beneficial effects (Ref. 57); but donor 
cell viability is drastically few months after 
transplantation.  As Hilbert and Koolbergen 
documented, instead of the donor cells, the valvular 
surface is covered by a fibrous sheath (Ref. 58, 59). 
It is known that homograft immunogenicity is 
directly related to cell viability (Ref. 60). 
Cryopreserved homografts have been shown to 
elicit a donor-specific immune response at humoral 
and cellular levels (Ref. 61, 62). The necessity to 
address or not crossmatch for blood group is a clear 
example of contradictory opinions on this issue 
(Ref. 63, 64, 65). In any case, since endothelium is 
especially pointed for valve immunogenicity (Ref. 
66), a strategy based on the elimination of this layer 
during tissue processing could be used to reduce 
this risk. Nevertheless, although host cells can 
colonize the matrix, endothelium reconstitution 
seems to be difficult (Ref. 60, 67) and the loss of 
this layer may lead to detrimental effects on the 
ECM (Ref. 59). Additionally, to what extent the 
immunological response affects homograft 
durability is still unclear (Ref. 66, 68, 69, 70)). 
Other factors noted above can lead to apoptosis of 
donor cells in the transplanted homograft: 
prolonged ischemia, addition and removal of 
cryoprotectant solution, cooling and warming rates, 
ischemia-reperfusion injury (Ref. 58, 71). 
Homograft degeneration probably reflects the 
cumulative damage of several factors. 
The use of proper manufacturing and storage 
practices to preserve the homografts until the 
moment of their transplant is also a key issue in the 
success of the implant. For this reason, cell and 
tissue banks and transplant organizations are the 
key guardians for preserving safety. The critical 
issues that may affect the safety and efficacy of the 
homografts are: 
• Disease Transmission: Rigorous donor 
screening is actually the best available 
method to improve allograft safety (Ref. 72, 
73). 
• Tissue Assessment: Quality codes are 
assigned to homografts, depending on the 
presence of calcification, atheromas or 
fenestrations a morphological status is 
determined (Ref. 72, 74). These 
classifications are crucial during the 
decision-making process for tissue 
allocation. 
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• Contamination: Tissue microbial 
contamination may arise from several 
sources such as the operation team (Ref. 
75), the own donor, especially if death is 
caused by trauma or the heart has been 
recovered late after death. In order to 
prevent contamination, the control of 
processing area is also crucial. The 
homograft extraction needs to be performed 
in an aseptic clean room with grade B 
background and under sterile conditions (air 
quality class A) (Ref. 76). If the 
replacement needs to be frozen, storage in 
liquid nitrogen needs to be strictly 
controlled. Liquid nitrogen is not sterile and 
microorganisms survive at this ultra-low 
temperature (Ref. 77). A liquid environment 
acts as an efficient vehicle for microbial 
diffusion. For this reason, the bag 
containing the tissue is doubly wrapped 
using another bag (so called double-
bagging), and sealed. It is common practice 
in cardiac valve banks, to ensure the 
immersion of tissues in an antibiotic 
cocktail immediately following collection. 
The length and temperature of incubation, 
as well as the concentration and type of 
antibiotics used, vary among banks (Ref. 
78). 
• Cell and tissue damage: Heart valve 
processing is not harmless and some 
important factors must be controlled to 
enhance cell viability (Ref. 71). Those 
factors are ischemia (Ref. 79, 80), freezing 
and thawing conditions (Ref. 81), or 
disinfection and storage of the samples 
before their use. 
Native heart valves are dynamic structures that are 
in continuous remodelling to adapt the 
hemodynamic necessities. As we already 
mentioned, interstitial cell viability may enable 
continuous remodelling (Ref. 66, 82) and 
fibroblastic matrix cells are immunologically well 
tolerated. Koolbergen et al. found fibroblastic 
donor cells in vessel walls several years post-
transplantation (Ref. 67). 
None of the current replacements is able to restore 
completely the capacities and functions of native 
valves, so in the end, after several years cardiac 
function may be compromised. As we already 
mentioned, this is especially crucial for children 
and young adults suffering cardiac valve problems. 
In those cases, as well as in particularly active older 
people, the most successful valve replacement 
approach is the Ross procedure (Ref. 16). This 
procedure is a specialized valve surgery where the 
diseased aortic valve is replaced by patient's own 
pulmonary valve, and then this is substituted with a 
cadaveric pulmonary homograft. Ross procedure 
offers several advantages over replacements with 
biological or mechanical prosthesis. 
First, in the case of paediatric patients, the 
pulmonary autograft can continue growing in the 
aortic position according with the recipient with 
higher longevity than xenografts. Anticoagulation 
treatment, which is required for mechanical 
replacements, is not necessary after Ross 
procedure. This is especially beneficial for women 
that want to have children because anticoagulation 
drugs are contraindicated during pregnancy. 
However, especially in the case of children, this 
replacement procedure may fail. After the 
relocation in aortic position, pulmonary valve 
composition can be altered due to the higher 
biomechanical demand that aortic valve supports. 
Additionally, the pulmonary autograft transplanted 
during Ross procedure, needs to be replaced at 
some point (Ref. 65, 83). Despite the fact that 
human homografts seem to be the most 
physiologically suitable substitutes (Ref. 11), the 
number of cadaveric donor valves cannot meet 
current demands. For this reason finding a suitable 
TE solution is especially challenging in paediatric 
or young patients. 
4. Tissue-engineered heart 
valves 
Heart valve tissue engineering represent a 
promising strategy to create prostheses with similar 
functional and biomechanical properties to native 
heart valves (Ref. 84). They should be able to 
withstand the repetitive changes in shape, 
dimensions, and stress generated by the opening 
and closing cycles they are subjected to during 
cardiac beating (Ref. 85). Similarly, the TEHVs 
should solve some of the common limitations that 
still remain in commercially available prostheses 
and have a direct impact on the clinical outcome 
(Ref. 86): thrombogenicity, calcification, and high 
immunogenicity, among others. Poor 
biomechanical properties or inadequate ECM 
composition of TEHVs could induce stenosis, 
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valve regurgitation, or low transvalvular pressure 
gradient of the incumbent valve.  
Regarding paediatric patients, their implanted 
TEHVs should be capable of growing and 
remodelling according to the stage of patient's life, 
responding to biological signals, and initiating self-
repair operations after small damaging events in the 
same way that native valves respond. Eventually, 
the TEHVs should be able to integrate themselves 
into the patient's tissue. Taken together, these 
requirements should be accomplished whilst 
integrating all individual components of the TEHV 
into a synergistic design. 
The fabrication of functional, viable, and human 
implantable prostheses depends on three substantial 
components widely known as TE triad: cells, 
scaffolds, and signalling molecules (Ref. 87). The 
following sections focus on two of these building 
blocks and the decisions affecting them during the 
creation of TEHVs: the selection of the cell type 
and the fabrication of the scaffold. Clinical on-
going solutions and future possibilities based on TE 
are summarized in Figure 3 (options A, B, and C). 
Additionally, the progresses reached in TE through 
in vitro studies, preclinical studies, and clinical 
trials are summarized in Tables 2, 3, and 4, 
respectively. 
4.1. Challenge 1: Selecting 
biomaterials for scaffolds 
The success of the TEHV strongly depends on the 
biocompatible materials selected to construct the 
scaffold and the resulting physicochemical 
properties (Ref. 88). The scaffold is the three-
dimensional (3D) structure that allows cells to 
adhere, generate ECM, grow, migrate, and also 
differentiate. Some crucial processes that can 
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guarantee the full integration of the implant into the 
heart. 
The scaffolds of TEHVs face important challenges 
in terms of integrity, mechanical strength, 
calcification resistance, and thrombosis risk; but 
even more important, they must be prepared to deal 
with the cardiac environment conditions 
immediately upon implantation (Ref. 89). As 
shown in Figure 3, there are mainly two types of 
scaffold for HVTE: acellular native valves and 
artificially engineered scaffolds; in case of the 
latter, its constituents need to be carefully 
considered, since the aim is to mimic the native 
valve anatomy and functionality. 
Finally, the materials selected must be suitable for 
different manufacturing processes and reasonably 
accessible, enabling mass production that caters to 
the important demand in a shorter time than the 
currently available (Ref. 90). 
4.1.1. Decellularized cardiac valve 
scaffolds from allogeneic/xenogeneic 
sources 
Traditionally, decellularized heart valves and 
pericardium tissues from sheep, cows and pigs have 
been selected as scaffolds due to the shortage of 
human valve allografts (Ref. 91). The 
decellularization methods use detergents, chelating 
agents, proteolytic enzymes, or combinations 
thereof (Ref. 92). Other alternatives applied include 
the use of electrical pulses, hydrostatic pressure, or 
freeze-thaw cycles (Ref. 18).  
The main advantages of decellularization are the 
retention of the original structure as well as many 
ECM proteins, preservation of the mechanical 
properties, and a relatively low cost. However, 
there are serious limitations such as the possibility 
of disease transmission, or excessively high density 
and stiffness. Moreover, the porosity is especially 
low on valves decellularized and treated with 
crosslinking agents. A failure in the 
decellularization process has detrimental 
consequences for patients as shown in the 
SynerGRaft trial (Ref. 93). However, the necessity 
of re-seeding or not a valve after decellularization 
is still the subject of an intense debate. Some 
authors argue that in vitro recellularization is not a 
realistic strategy that can be translated into routine 
clinical practices because of its high financial and 
time costs (Ref. 94). Indeed, some studies 
demonstrate that the seeded cells do not survive 
when the valve is introduced into the patient and 
that the host’s cells may be the origin of the 
observed repopulation (Ref. 91). A summary of 
reported clinical experiences is given in Table 2. It 
should be noted that this strategy, which is labelled 
as B in Figure 3, is the one that has gone further of 
all TEHV approaches concerning clinical trials 
(Ref. 95, 96, 97).  
Important differences in cell growth when 
compared to human-source matrices were 
demonstrated after seeding human cells over them 
(Ref. 98). The use of multilayer VEGF/heparin or 
chitosan/heparin films to cover the decellularized 
valve has demonstrated to increase in vitro 
adhesion and proliferation of endothelial progenitor 
cells (EPCs). This has resulted in an improved 
decellularized valve haemocompatibility and a 
reduced risk of thrombosis (Ref. 99, 100). 
Although it has been proved that host cells can 
recolonize the scaffold, a study comparing native 
heart valves with decellularized and recolonized 
ones, concluded that the cell types present in the 
manipulated structures are different from the native 
ones. This may interfere in the normal function 
and/or stability of the valve. Additionally, the 
limited re-endothelization that can be achieved in 
decellularized matrices can compromise their 
integration and long term viability. In vivo 
recellularization studies have stated that pre-
treatment with host cells can improve scaffold’s 
biocompatibility reducing calcinosis (Ref. 101). 
Therefore, a short-term incubation of the scaffold 
with cells and/or unprocessed cell preparations 
from the patient seems to help in both the 
recellularization and cell survival outcomes (Ref. 
94, 102). Another alternative is to enhance 
autologous recellularization after implantation 
coating the acellular scaffolds with biological 
components (Ref. 100), or with CD133 antibodies 
(Ref. 103). 
4.1.2. Artificially engineered scaffolds 
The alternative to decellularization seems to be de 
novo construction of natural or synthetic scaffolds 
using biocompatible and biodegradable materials. 
The ideal artificial scaffold should take into 
account the anisotropy and heterogeneity of native 
valves. Two types of scaffold for TEHVs are 
usually created: fibrous and porous. The classical 
method for manufacture porous scaffolds has been 
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to mould thermoplastic biomaterials into 3D 
structures (Ref. 104, 105, 106). In the case of 
fibrous scaffolds, electrospinning, due to its 
applicability and simplicity, is by far the most 
commonly used technique to prepare the nanofibers 
for the scaffold. This technology is based on the 
continuous elongation of a viscoelastic flow 
derived from a polymer solution (Ref. 107). Drops 
of polymer, created with a syringe, are electrified 
and ejected by electrostatic repulsions, producing 
long and thin fibres. They are finally collected with 
a mould that can have easily the desired shape of 
the heart valve (Ref. 108, 109). Other technique is 
the knitting, in which 2D flat sheets with well-
interconnected pores are created using drawn 
filaments of polymer. However, current 
electrospinning moulding techniques and knitting 
systems may soon be replaced by more flexible 
additive manufacturing (AM) processes (Ref. 110). 
Most of the conventional manufacturing procedures 
generate components with different degrees of 
stiffness that need to be subsequently joined 
together by biocompatible suture or glues such as 
bovine serum albumin-glutaraldehyde (Ref. 111). 
AM can overcome these limitations. For instance, 
stereolithography is a technology more suitable to 
create complex and heterogeneous scaffolds. This 
technique first can create a scaffold of hydrogel, 
which is subsequently cross-linked with ultraviolet 
light (Ref. 112). Nevertheless, the use of cytotoxic 
wavelengths and the necessity of additional coating 
to improve cell adhesion means that further 
research in this field is imperative in order to find 
more realistic alternatives. 
A. Fabricated scaffolds from synthetic materials 
The production of synthetic scaffolds can be easily 
controlled allowing reproducibility, 
standardization, and stable properties. 
Theoretically, they are designed to create 
bioabsorbable matrices that act as transitional 
platforms until the seeded cells replace the 
synthetic polymers by natural ECM proteins. The 
synthetic scaffolds can be produced cost-effectively 
with enough strength and stiffness, and showing 
important advantages such as low thrombogenicity, 
and immunogenicity. However, their structural 
complexity, shape and elastomeric properties are 
still far from decellularized valves or native tissue. 
Numerous synthetic materials have been tested 
including, polyglactin (Ref. 113), polyglycolic acid 
(PGA) (Ref. 114, 115), polylactic acid (PLA), 
copolymer of PGA and PLA, (PLGA) (Ref. 104), 
polyhydroxyalkanoate (PHA) (Ref. 116), polyether 
urethane (PEU) (Ref. 117), polyester urethane urea 
(PEUU)  (Ref. 108), polycarbonate urethane (Ref. 
118), poly-ε-caprolactone (PCL) (Ref. 119),  
poly(glycerol-sebacate) (PGS) (Ref. 120),  
polydioxanone (PDO) (Ref. 109),  among others. 
While several combinations of these polymers can 
be found in the literature (Ref. 116, 119), few 
studies have systematically compared them to 
single ones; therefore, it is difficult to establish the 
prevalence of anyone of them over the rest. 
PHA seems to be the biomaterial family most often 
used for creating highly porous solid scaffolds 
when preparing scaffolds for 3-leaflet heart valves. 
On the contrary, most of fibrous scaffolds seem to 
be produced from PGA using mechanical drawing 
or electrospinning. PHA shows a wide range of 
mechanical and thermal properties, but, above all, it 
stands out because it may be manipulated using a 
wide range of processing techniques (Ref. 105). 
Mitchell et al. demonstrated that the vascular 
scaffolds made of polyglactin/PGA copolymer 
were unstable, inducing aneurysm formation (Ref. 
121). PGA combined with PLA improves scaffold 
properties such as less water absorption and 
reduced degradation rate (Ref. 86, 122, 123, 124). 
Stock et al. proved the superior properties of using 
hydroxyoctanoate (PHO) instead of PLA in terms 
of cell proliferation and scaffold stiffness (Ref. 
125). PGA/PHO scaffolds coated with laminin and 
seeded with endothelial cells and vascular medial 
cells produced functional TEHVs after implanted in 
animals for up to 6 months. Also it has been 
described the thermo-plasticity showed by 3-leaflet 
valve scaffolds of nonwoven PGA mesh coated 
with poly-4-hydroxybutyrate (P4HB) (Ref. 4, 106).  
The synthetic scaffolds can be coated with ECM 
proteins such as those present in plasma or platelet 
enriched plasma (Ref. 126) or other proteins such 
as growth factors, which enable targeted promotion 
of particular tissue growth (Ref. 26). ECM proteins 
provide not only additional structural support but 
also cell receptors, and binding sites (Ref. 127, 
128). Their use improves the biocompatibility of 
the scaffold, and provides better cell adhesion, 
growth and differentiation. Therefore, as a natural 
evolution to the use of synthetic valves, the 
scaffolds can also be constructed with biological 
ECM proteins. 
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B. Fabricated scaffolds from natural materials 
Various studies have reported the use of collagen, 
hyaluronic acid (HA), fibrin, chitosan, or 
combinations thereof, to create biological protein 
based scaffolds (Ref. 111, 129, 130). Moulded 
TEHVs composed of fibrin gel and fibroblasts 
(FBs) have already been produced with the capacity 
to withstand backpressure commensurate with 
aortic valves in regurgitation tests (Ref. 131). In a 
sheep model, a pilot study demonstrated the 
potential of fibrinogen to create TEHVs with 
excellent tissue remodelling and structural 
durability after 3 months in vivo (Ref. 132).  
A summary of representative in vitro studies using 
different biomaterials and manufacturing methods 
is given in Table 3. Note that many of the in vitro 
studies highlight the resulting constructions are 
characterized by weak matrices and poor 
mechanical properties. This and the fact that it is 
hard to obtain sufficient amount of the proteins 
required, indicate that alternative sources, such as 
cultured human cells, should be found to avoid the 
risk of zoonosis from animal components (Ref. 
133). It is certainly clear that human collagen or 
fibrin-based valves are far from being feasible. 
4.1.3. Other approaches for HVTE 
Among other AM approaches, 3D printing is one of 
the most promising technologies that would allow 
the construction of fully customized TEHVs with 
accurate geometry, and controlled properties 
designed to suit patients’ specific needs. Enhanced 
levels of complexity might be achieved by the 
inclusion of various materials and cell types 
simultaneously at each step of the manufacturing 
process (Ref. 134). A proof of concept has already 
been performed by Butcher’s group using the open-
source 3D printer Fab@home (Ref. 112, 135). In 
general, this approach uses cell encapsulated in 
synthetic and/or natural hydrogels to generate 
heterogeneous and multi-scaled biological 
constructions. For instance, inkjet printing, which 
can fuse scaffold construction and recellularization 
into one step, allows the addition of different cell 
types during valve generation providing a better 
integration of the components (Ref. 136). All of 
these are still early stage technologies that promise 
less labour-intensive fabrication of patient-specific 
TEHVs. 
4.2. Challenge 2: Cell candidates for 
TEHVs 
In all TE systems, the cells are the commanders of 
regeneration, while the rest of the components act 
as a biological support (Ref. 137). For this reason, a 
proper selection of the cell types is the key part to 
succeed. An ideal candidate must satisfy the 
following criteria. First, cells should be in the 
appropriate differentiation status for re-establishing 
the desired functions, supporting mechanical loads, 
and synthesizing ECM proteins (Ref. 12). Second, 
they should be immune-compatible. So, the best 
scenario would be the use of autologous cells 
because native heart valve cells have the most 
suitable phenotype, and the potential to synthesize 
ECM and remodel the bioscaffold (Ref. 138); 
however, their low availability, and the isolation 
and maintenance difficulties associated with them 
are serious impediments.  
In this section, we present recent progress in the 
search for cell candidates as well as some 
conclusions derived from the studies performed. 
The cell types selected should be able to produce 
all cell populations in the heart valve. To cover 
these issues we include in this paper the advances 
made in HVTE using different cell types such 
embryonic stem cells (ESCs), induced pluripotent 
stem cells (IPSs) and even foetal cells, which 
represent the main candidate to generate prenatal 
constructs (Figure 3). 
4.2.1. Adult Stem cells 
A. Vascular endothelial cells 
They play an important role in valvular function, 
reducing the risk of coagulation and preventing 
inflammatory complications. If they are maintained 
in static culture, the vascular ECs share some 
similarities with VECs but under steady flow, as 
we mentioned above, the vascular ECs align 
perpendicularly to flow direction as vascular 
smooth muscle cells (SMCs) do (Butcher, 2004 
#390). For this reason, different vascular ECs have 
been tried as a source for VECs. 
Several groups have used the vascular tissue as a 
source for extract VECs and recellularize different 
scaffolds. For example, vascular myofibroblasts 
(MFs) from human aortic tissue can survive and 
generate mature collagen matrix in ECM-coated 
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PGA scaffolds (Ref. 139), fibrin gel structures 
(Ref. 140), and scaffold-free tissues (Ref. 141, 
142). More accessible venous tissue, such as the 
saphenous vein, can also be useful for isolating 
MFs. These produce harder and more mechanically 
resistant ECM than their arterial counterparts (Ref. 
143, 144). 
In some cases, those works have also get ahead 
towards in vivo studies using animal models. 
Pulmonary valve leaflets were exchanged by PGA 
scaffolds and then seeded with arterial FBs and 
vascular ECs in lambs (Ref. 113). Additional 
studies were able to prove that the implanted cells 
were still alive 8 weeks after transplantation (Ref. 
114). This approach was improved by the addition 
of a preconditioning step and coating the scaffold 
with P4HB (Ref. 145). 
The same seeding strategy, but with autologous 
MFs and vascular ECs, was attempted in 
decellularized sheep heart valves. Although a 
complete restitution was observed, histological 
signs of inflammatory reaction were observed in 
the subvalvar muscle (Ref. 146). Autologous 
arterial vascular ECs seeded on fibrin scaffolds 
were also capable of integrate in adult sheep 
pulmonary valves; but some degree of leaflet 
insufficiency after 3 months follow-up was 
revealed due to tissue contraction (Ref. 132). This 
issue may be resolved by the addition of other 
proteins in the scaffold to increase its resistance 
and stability. The feasibility of vascular tissue-
derived cells has also been evaluated in several 
clinical trials. A decellularized cryopreserved 
pulmonary allograft was seeded with autologous 
vascular ECs isolated from patient’s forearm vein 
to create a viable TEHV; the right ventricular 
outflow tract was successfully reconstructed after 
Ross procedure (Ref. 147). Similar results were 
observed in 11 patients at 10 years follow-up (Ref. 
148). Same procedure, but with porcine 
decellularized valves, did not show any statistically 
significant difference with the allografts, opening 
the possibility to solve the limitations of allografts 
(Ref. 149).  
The use of non-valvular ECs in an aortic valve 
substitute, may sacrifice important functional 
behaviour. It is currently unknown if the dissimilar 
responses of vascular ECs and VECs  against fluid 
flow has any effect on overall leaflet function, but 
different responses may imply altered paracrine 
signalling to surrounding cells. The main 
shortcomings of the vascular ECs are their limited 
availability and low proliferation rate. Moreover, 
the potential benefits are scarce because isolation of 
autologous cells requires the destruction of healthy 
structures and harmful surgical procedures (Ref. 
150).  
B. Endothelial progenitor cells 
Circulating EPCs (Ref. 151) are one of the most 
promising cell types to solve the problem of the 
amount of ECs needed for engineering HVs. These 
cells, characterised by the expression of CD34 and 
VEGF2, are able to proliferate and generate 
endothelial structures both in vitro and in vivo (Ref. 
152). EPCs are supposed to be recruited towards 
cardiac tissue in patients with coronal problems 
such as aortic valve regurgitation, dysfunctional 
congenitally-bicuspid aortic valves,  aortic valve 
stenosis, or after coronary artery bypass grafting 
(Ref. 153, 154, 155, 156, 157). EPCs express 
endothelial markers such as CD31, VE-Cadherin, 
and eNOS; and after seeding they also express αSM 
actin, MMP2/9, and metalloproteinase inhibitors 
(Ref. 158, 159). Treatments with VEGF and 
TGF1β can induce EPC endothelial to 
mesenchymal transition. In fact, some authors 
suggest that they correspond to the hypothetical 
group of valvular progenitors that controls normal 
heart valve repair (Ref. 160). 
The potential of EPCs in TEHV has been tested in 
few in vitro (Table 2) and in vivo studies with 
encouraging results. A summary of some of the 
most representative pre-clinical investigations 
involving different HVTE strategies is given in 
Table 3. Coating a PGA scaffold with P4HB was 
found to improve EPC adhesion (Ref. 115, 158), 
similarly, the generation of a heparin/VEGF or 
chitosan/VEGF multilayer film increased EPC 
proliferation, adhesion, and migration in 
decellularized porcine aortic valves (Ref. 99, 100). 
Their feasibility has also been tested in vivo 
through a clinical study performed by Cebotari et 
al. (Ref. 161). A three and a half year follow-up on 
two paediatric patients who underwent surgical 
implantation of human pulmonary valves incubated 
with peripheral mononuclear cells containing EPCs 
showed some remarkable findings: Both patient’s 
valves had significantly increased in size as the 
patients matured without any sign of valvular 
degradation, and only mild regurgitation was 
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observed. Nevertheless, the exact role of the EPCs 
in this improvement remained unclear. 
C. Mesenchymal stem cells from bone marrow 
Because VICs have an intermediate endothelial-
mesenchymal behaviour and phenotype, 
mesenchymal stem cells (MSCs) are also being 
widely studied. These cells can be expanded easily 
in vitro, differentiate into several cell lineages, 
produce and organise ECM in a very similar way to 
native heart valve cells (Ref. 162), and can also 
respond to mechanical stimuli, adapting their 
morphology, marker expression, protein 
production, and migration (Ref. 163). Moreover, 
they also have important immunomodulatory 
properties (Ref. 164). In the two following sections 
we detail the most important sources of MSCs and 
their properties. 
Probably the most characterised source of adult 
MSCs is the stromal fraction of BMSCs which 
have non-hematopoietic mesenchymal features and 
share more than 80% of their markers with VICs 
(Ref. 165). Experiments with chimeric mice 
transplanted with green fluorescent protein (GFP)-
expressing BMSCs demonstrated that they are 
recruited to the heart valve as part of normal 
homeostasis (Ref. 28, 166), and that their 
circulation and recruitment is also enhanced in 
patients who underwent coronary surgery. 
Similarly granulocyte-colony-stimulating factor 
treatment in a clinical trial was also shown to 
promote BMSC mobilisation towards heart valves, 
although no significant functional improvement 
was observed compared to untreated patients. 
BMSCs have a good capacity to adhere, colonize, 
proliferate, and differentiate when seeded into 
many types of synthetic materials such as 
PGA/PLA (Ref. 86, 122, 123, 124), PGA/PH4B 
(Ref. 167, 168), or poly-propylene carbonate (Ref. 
169); but also into biological collagen scaffolds 
(Ref. 111), fibrin complexes (Ref. 170, 171, 172, 
173), and decellularized tissues (Ref. 171, 172, 
173).  
In general, these in vitro studies concluded that 
BMSCs produced stable structures with an ECM 
and cellular composition very similar to the native 
valve. BMSCs have been also used to perform in 
vivo studies. For example, autologous BMSCs 
seeded in a biodegradable PGA/PLLA scaffold 
were implanted in sheep allowing long-term 
functional recuperation (longer than 4 months)(Ref. 
86). Similar experiments using neonatal BMSCs 
also concluded that the construct diameter 
remained unaltered after 20 weeks, although 
pulmonary regurgitation was detected after 6 weeks 
due to the decrease in the cusp dimension (Ref. 
124).   
The process of BMSCs differentiation towards a 
VIC-like phenotype has been addressed from 
various perspectives. The classical epigenetic 
stimulation has been conducted with vascular 
endothelial growth factor (VEGF) and transforming 
growth factor β1 and β2 (TGFβ1, TGFβ2) (Ref. 
171). Apart from these two, it has been also tested 
the vector-induced expression of the fibroblast 
growth factor-inducible 14 (Fn14) differentiation 
factor (Ref. 174) and other functional proteins such 
as eNOS (Ref. 169). Nevertheless, exposure to 
mechanical stress is essential for their full 
differentiation toward ECs: after flow-rate 
stimulation BMSCs showed better integration into 
the scaffold, differentiation, migration, and ECM 
production (Ref. 175). This phenomenon is not 
exclusive to BMSCs and it has been also reported 
in EPCs and adipose-derived stem cells (ADSCs), 
among others.  Moreover, this effect was even 
higher with combined flex-stretch-flow treatment in 
special bioreactors (Ref. 111, 123, 176).  
BMSCs can generate cells from many cell lineages. 
Nevertheless, the complete differentiation of the 
total population must be addressed carefully, not 
only to obtain fully functional cells, but also to 
reduce the possibility of transdifferentiation. For 
example, BMSC exposure to mechanical tension 
seems to induce the expression of chondrogenic 
and osteogenic proteins, promoting valve 
calcification and compromising graft viability (Ref. 
177). Comparative studies with ECs and SMCs 
revealed that constructions seeded with CD133+ 
BMSCs showed lower calcification and 
inflammation accompanied by a higher 
transvalvular gradient (Ref. 178). 
Another important issue is that proliferation and 
differentiation of BMSCs may be altered in older 
patients, thus, bone marrow might not be a viable 
source of autologous cells in many of these patients 
(Ref. 173). 
Some authors have worked directly with the bone 
marrow mononuclear cell (BMMC) fraction. This 
cell type shows a remarkable potential to adhere, 
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grow, and differentiate in GA-fixed valves 
detoxicated with citric acid (Ref. 179), or coated 
with plasma or platelet-enriched-plasma (Ref. 126), 
but his was not the case of fibrin-coated synthetic 
scaffolds. BMMCs seeded and incubated with them 
for short amounts of time did not increase cell 
integration after implantation neither in sheep (Ref. 
94) nor in non-human primates (Ref. 180). 
Compared to BMSCs, the recellularization of 
porcine scaffolds with BMMCs produced a higher 
inflammatory cell infiltration and valve thickness 
(Ref. 172).  This reaction is maybe due to the fact 
that BMMC fraction attracts endogenous cells such 
as monocytes, promoting regeneration via adjacent 
blood vessels (Ref. 181). 
D. Mesenchymal stem cells from adipose tissue 
Among the MSCs obtained from other sources, 
human ASCs have emerged as strong candidates to 
play a crucial role in TE and regenerative medicine 
for several reasons. They can be easily harvested 
from an abundant source, the fat tissue. The cell 
yield per gram of fat tissue is about 500-fold that 
obtained for BMSCs (Ref. 182, 183). They can be 
isolated with greater success than in other foetal or 
adult sources due to their higher colony-forming 
unit capacity (Ref. 184, 185). ASCs show high rate 
of proliferation in vitro and have multipotent ability 
to differentiate towards different types of MSC. 
Therefore, ASCs can be a virtually infinite supply 
of SCs, making them not only a good candidate for 
heart valve construction but also for generating 
other cardiac structures such as vascular bypass 
grafts (Ref. 186).  
The ASCs, like their bone marrow counterparts, do 
not trigger the response of allogeneic lymphocytes 
in vitro (Ref. 187).  They have an 
immunophenotype which is very similar to other 
MSCs, however, no studies have been performed to 
test their potential in vivo. One of the reasons could 
be that  although they are capable of undergoing 
mesenchymal to endothelial transformation in 
response to mechanical changes or to the addition 
of factors like VEGF, current differentiation 
methods do not produce cells capable of expressing 
important markers such as eNOS (Ref. 188, 189).  
The ASCs have shown a great potential in the 
preliminary studies in vitro. When their behaviour 
in PGA/PH4B scaffolds is compared with human 
BMSCs or VICs, they showed higher elastin, 
collagen, and GAG production; they also have a 
higher migration rate and are more uniformly 
distributed within the scaffold, which is thought to 
be due to their higher expression of α-SM actin 
(Ref. 162). Further experiments in order to 
optimize their final differentiation to adapt them to 
the cellular requirements must be address to test the 
feasibility of this promising source of cells. 
4.2.2. Prenatal extraembryonic cell 
sources 
In addition to the abovementioned adult SCs, foetal 
and extra-foetal tissues represent additional sources 
of SCs. As we mentioned above the paediatric 
problem is one of the challenges in cardiovascular 
treatments. The finding of autologous, viable and 
growing replacements such as TEHVs would 
reduce the insurmountable therapeutic limitations 
in the treatment of children carrying congenital 
heart diseases. The majority of these cardiac 
defects can be detected around week 20 of 
pregnancy. Autologous stem/progenitor cells can 
be isolated from several of the foetal annex 
structures, without damage or compromise the 
foetus itself. The relevant cells prenatally harvested 
are amniotic fluid-derived cells (AFDCs), chorionic 
villi-derived mesenchymal progenitor cells, and 
umbilical cord blood (UCB) derived EPCs (Ref. 
102). The cells obtained show a higher expansion 
rate and plasticity to produce a wider variety of cell 
lineages that can be used for autologous TEHV 
implants at birth or prenatally.  
A. Amniotic fluid-derived cells 
Amniotic fluid represents an attractive foetal cell 
source for the concept of paediatric heart valve 
tissue engineering since it renders possible prenatal 
access to foetal cells from all three germ layers via 
a low-risk procedure (Ref. 150). The amniotic 
fluid, generally obtained from amniocentesis or 
amnioreduction, contains a heterogeneous cell 
population with a small percentage of cells 
showing stem cell features (Ref. 190). The AFDCs 
present not only an intermediate growth rate 
between embryonic and MSCs, but also a 
phenotype which includes early stemness markers 
and MSC-like signatures (Ref. 191, 192). In fact, 
AFDCs can be reverted into a pluripotent state or 
generating ECs after adequate stimulation (Ref. 
193, 194). The feasibility of generating living 
autologous heart valve leaflets in vitro using human 
amniotic fluid as a single cell source and also by 
combination of mesenchymal ADCs with amniotic 
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fluid endothelial precursors has been already 
attempted  (Ref. 195). This research group also 
demonstrated the in vivo functionality of 
autologous AFDCs seeded over biodegradable 
PGA/P4HB scaffolds and transplanted into sheep 
fetuses before birth (Ref. 196, 197). 
B. Chorionic villi-derived mesenchymal stem 
cells 
The chorion is one of the membranes that conform 
the human placenta. This membrane is composed 
for maternal mesoderm tissue embedded between 
mesenchymal and trophoblastic cells with foetal 
origin, called chorionic villi. Biopsy of chorionic 
villi cells is routinely performed for prenatal 
genetic diagnostics because provides foetal 
mesenchymal cells, including foetal progenitor 
cells, located out of the foetus. 
When isolated from an early developmental stage, 
chorionic villi cells exhibit profound stem cell-like 
properties, for this reason they are a promising cell 
source for paediatric tissue engineering applications 
(Ref. 102). Schmidt et al. (Ref. 196) have 
demonstrated the feasibility of this approach for 
HVTE by using chorionic villi-derived 
mesenchymal cells for the fabrication of viable 
heart valve leaflets in vitro, with promising results. 
The greatest roadblock in these initial studies is the 
overgrowth of maternal cells, that sometimes are 
also present in the samples a fact that needs to be 
avoided in the future., chorionic villi samples also 
contain foetal capillary endothelial cells, which 
might also be isolated using cell sorting techniques 
as part of future therapeutic attempts (Ref. 198). 
C. Umbilical cord blood derived-endothelial 
progenitor cells 
The umbilical cord is a common source of 
hematopoietic cells, but it may also become an 
invaluable source of non-hematopoietic SCs, the 
UCB-derived EPCs. They are attractive candidates 
for enhancing the biocompatibility of mechanical 
valves. UCB-derived EPCs have already been 
successfully used to seed decellularized valves 
(Ref. 199), and mechanical valves made of 
hydroxyapatite (Ref. 200), or titanium (Ref. 201). 
The idea of reseed a graft using this cell type would 
be specially useful in cases of fetal cardiopathies 
that require valve replacement. Furthermore, 
human UCB-derived FBs and EPCs have been 
successfully used to generate living patches on 
PGA/P4HB scaffolds (Ref. 202) and tissue-
engineered blood vessels (Ref. 203). In order to 
assure their feasibility, it must be tested whether 
these cells can acquire the dual mesenchymal-
endothelial phenotype, which is required for their 
proper function in the tissue. 
4.2.3. Embryonic and induced 
pluripotent stem cells 
Embryonic stem cells (ESCs) are theoretically 
capable of recapitulating the whole valvulogenesis 
process. Indeed, their high expansion rate and 
pluripotency make them stand out from other cell 
types. Ethical issues could be overcome using non-
destructive embryonic manipulation methods; 
however, and despite their demonstrated potential, 
two important shortcomings discourage their use in 
TE applications: high risk of teratoma formation 
and xenorejection. The latter could be 
circumvented by the use of induced pluripotent 
stem cells (iPSCs). Despite of their adult tissue 
origin, iPSCs are grouped together with ESCs due 
to their similarities and pluripotent capacities.  
iPSCs are generated by inducing the expression of 
certain stemness genes in adult differentiated cells 
extracted from patient’s own tissues (Ref. 204). 
Recently, they have been proven to be capable of 
repopulating decellularized mouse heart valves 
(Ref. 205), but the generation of functional TEHVs 
requires further research, especially in controlling 
cell differentiation. Although the promise of 
revolutionary improvements in TE, patient-derived 
iPSCs are still far from clinical practice; they still 
represent valuable models to study the origin and 
development of heart valves. 
5. Conclusion and future 
outlook 
The ideal replacement for heart valves would be an 
alive and immune-compatible implant containing 
both endothelial and interstitial cells. These cells 
must produce and remodel the appropriate ECM to 
address the growth of the graft in accordance with 
patient’s development. The structure of the TEHVs 
also needs to be fully functional in terms of 
hemodynamics and biomechanics immediately 
upon implantation. For now, none of the available 
solutions in the market accomplish all these 
requirements.  
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Mechanical and biological heart valve prosthesis, 
as mentioned before, continue as the gold standard 
in surgical replacement procedures, saving millions 
of lives. However,  both lack the properties of 
living replacements, with the subsequent inability 
to regenerate and growth. Additionally, mechanical 
substitutes also carry with them the side effects of 
anticoagulation drugs. For the moment, homografts 
and autografts appear to be the best clinical 
solution. But considering the evolution of modern 
society, the age of potential homograft donors is 
constantly increasing because of the aging of the 
population in general. This suggests that the 
availability and quality of the donated organs is 
decreasing. In addition, the heterogeneous cellular 
composition of native valves indicates that different 
cell types should be seeded sequentially or 
simultaneously to reach the most realistic approach 
to create TEHVs. Innovative advances such as non-
invasive imaging systems to monitoring the tissue 
regeneration or new flexible manufacturing 
techniques might be introduce in the equation. For 
all these reasons we firmly believe the best solution 
to this important social-sanitary problem is yet to 
come and probably remains hidden in the 
laboratory. 
We have come a long way since Vacanti attempted 
the creation of a TEHV almost 20 years ago. The 
progress is remarkable in many senses, especially 
due to recent advances on SC and biodegradable 
scaffolds, but few advances in HVTE have reached 
clinical stage. This can be due to several reasons, 
often interrelated; in our opinion, and considering 
the heterogeneous cellular composition of the 
native valves, the complexity of constructions 
needs to be drastically increased. Current scaffolds 
also fail to provide the proper properties in terms of 
morphology and biomechanics that promising 
artificial implants require to be capable of 
addressing current limitations of donor supply 
shortage. They also need to be manufactured with a 
composition and internal structure that makes them 
able to convey and release growth factors required 
in the cell niche of TEHVs. 
Additional effort must be given to assess the safety 
and efficacy of TEHVs before they will be ready to 
clinical routine. First, based on accumulated 
experience, it is mandatory to standardize and 
optimize the combinations of different candidate 
cells, biomaterials and culture conditions, 
establishing the criteria to correlate in vitro 
outcomes with in vivo experiments. Deeper in vitro 
characterization of TEHVs at structural and 
functional levels should be carried out, and 
additional strategies and criteria are required to this 
end. Current in vivo models must be replaced by 
others that better reflects the properties of human 
cardiac valves. Until now, the ovine model is 
routinely employed in preclinical studies, but the 
hemodynamic characteristics of sheep valve 
significantly differ from human ones. Therefore 
this might not be a good model to perform 
preclinical studies. 
Finally, it would be very beneficial for the field to 
join efforts and obtain global conclusions about the 
on-going research on HVTE. In this sense, the 
creation of databases for lending the 
standardization of in vitro TEHV results should be 
an interesting strategy. Develop an strict preclinical 
(in vitro and in vivo) quality control criteria before 
attempt clinical trials is also mandatory. Finally, 
enormous research effort will be also necessary to 
analyse and predict the individual response among 
patients. 
In our opinion, progress in the field will require 
laboratories with advanced technologies and novel 
manufacturing strategies and multidisciplinary 
teams in which close collaboration between 
developmental biologists, surgeons, engineers, 
polymer chemists and pharmacists will provide 
new insights. Without any doubt, we can asses that 
it will be sometime before we will find the perfect 
match able to mend a broken heart. 
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10. Figures and captions 1 
FIGURE 1. Photographs of human semilunar heart valves: aortic (a) and pulmonary (b). 2 
FIGURE 2. Detailed heart valve structure. It is composed of 3 inner layers (ventricularis, 3 
spongiosa and fibrosa) and an outer layer formed by valvular endothelial cells (VECs). The three 4 
inner layers contain mainly proteoglycans (PGs), glycosaminoglycans (GAGs), collagen type I and 5 
type III, elastin, and valvular interstitial cells (VICs). Adapted from (Ref. 206). 6 
FIGURE 3. On-going clinical treatments and future possibilities in heart valve tissue 7 
engineering (HVTE). The methods to create autologous constructs are a potential alternative to 8 
overcome the main drawbacks of traditional bioprosthetic and mechanical valve prostheses 9 
(Strategy A). The creation of tissue-engineered heart valves starts from the decellularized or 10 
synthetic scaffold, which represents the basic platform where cells proliferate. This can be directly 11 
implanted without (Strategy B) or with reseeding cells (Strategies C and D). Different cell types 12 
could be candidates for this purpose: vascular endothelial cells (VECs), bone marrow mesenchymal 13 
stem cells (BMSCs), induced pluripotent stem cells (iPSCs), chorionic villi-derived mesenchymal 14 
progenitor cells, umbilical cord blood (UCB) derived endothelial progenitor cells (EPCs), and 15 
adipose-derived stem cells (ASCs), among others. 16 
17 
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 18 
10. Tables 19 
TABLE 1. The different phenotypes and roles of the valvular interstitial cells (VICs) 20 
Cell type Role Location Ref. 
Embryonic 
endothelial 
progenitor cells 
(EPCs) / 
mesenchymal 
stem cells 
(MSCs) 
-Precursors of VICs that can be localized during  
valve development. 
- During endothelial-to-mesenchymal transformation 
stage, those precursors, move from the endothelial 
layer invading the cardiac jelly of the endothelial 
cushion where they proliferate and differentiate into 
VICs. 
 
Migrating (22) 
Quiescent 
valvular 
interstitial cells 
(qVICs) 
- Maintenance of heart valve structure and its 
functions. 
- Regulation of extracellular matrix (ECM) related 
processes. 
- Inhibition of angiogenesis. 
In the 3 
layers 
(207) 
Activated 
valvular 
interstitial cells 
(aVICs) 
- After damage, aVICs increase the number stress 
fibres and α-SMA expression, transforming them into 
VICs. 
- Increase cytokine secretion and ECM remodelling. 
- Once the process is achieved aVICs are removed via 
apoptosis. 
- Failures in the process result in pathological states. 
- Therapeutic targets. 
In the 3 
layers 
(24, 25) 
Progenitor 
valvular 
interstitial cells 
(pVICs) 
- pVICs express endothelial and mesenchymal 
markers. 
- Circulating progenitors from bone marrow. 
- Capable of differentiating towards aVICs directly or 
via a qVIC step. 
Circulating (26, 27, 28) 
Osteoblastic 
valvular 
interstitial cells 
(obVICs) 
- Promote calcification. 
- obVICs control the deposition of ECM that is 
responsible for heart valve calcification in 
pathological processes. 
Unknown (29) 
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d 
re
op
er
at
io
n.
 E
xc
el
le
nt
 h
em
od
yn
am
ic
 
pe
rf
or
m
an
ce
, n
o 
si
gn
s o
f c
al
ci
fic
at
io
n 
af
te
r 5
 y
ea
rs
. 
(1
61
, 1
48
, 
14
9)
 
C
ry
oV
al
ve
®
 S
G
 
C
ry
oL
ife
 
Pa
ed
ia
tri
c 
pu
lm
on
ar
y 
va
lv
e 
N
o 
ce
lls
 
- 
- 
N
o 
- 
31
4 
Pu
lm
on
ar
y 
 
Im
pr
ov
ed
 c
lin
ic
al
 o
ut
co
m
es
 a
nd
 h
em
od
yn
am
ic
 fu
nc
tio
n 
co
m
pa
re
d 
w
ith
 p
re
vi
ou
s m
od
el
s, 
re
du
ce
d 
pu
lm
on
ar
y 
in
su
ff
ic
ie
nc
y 
af
te
r R
os
s p
ro
ce
du
re
 a
nd
 ri
gh
t v
en
tri
cu
la
r 
ou
tfl
ow
 tr
ac
t r
ec
on
st
ru
ct
io
ns
 
(2
11
) 
En
ga
ge
r 
M
ed
tro
ni
c 
B
ov
in
e 
pe
ric
ar
di
al
 
le
af
le
ts
 in
 se
lf-
ex
pa
nd
in
g 
fr
am
e 
N
o 
ce
lls
 
- 
- 
N
o 
- 
30
 
A
or
tic
 
6;
 1
2 
6-
m
on
th
 su
rv
iv
al
 5
6.
7%
, c
om
pl
ic
at
io
ns
 d
ue
 to
 tr
an
s-
ap
ic
al
 d
el
iv
er
y,
 p
ac
em
ak
er
 im
pl
an
ta
tio
n 
in
 3
 p
at
ie
nt
s. 
N
o 
st
ru
ct
ur
al
 fa
ilu
re
 o
bs
er
ve
d 
af
te
r 1
 y
ea
r. 
(2
12
) 
Po
rti
co
 
St
. J
ud
e 
M
ed
ic
al
 
B
ov
in
e 
pe
ric
ar
di
al
 
le
af
le
ts
 w
ith
 
ni
tin
ol
 fr
am
e 
N
o 
ce
lls
 
- 
- 
N
o 
- 
10
 
A
or
tic
 
1;
 6
0 
In
 3
0 
da
ys
, g
oo
d 
he
m
od
yn
am
ic
 p
er
fo
rm
., 
m
ild
 
re
gu
rg
ita
tio
n 
in
 9
 p
at
ie
nt
s. 
R
el
oc
at
io
n 
in
 4
 p
at
ie
nt
s, 
re
-
im
pl
an
ta
tio
n 
in
 1
 p
at
ie
nt
. L
on
g 
te
rm
 o
bs
er
va
tio
na
l 
pr
og
ra
m
 c
an
ce
lle
d 
du
e 
to
 re
du
ce
d 
le
af
le
t m
ob
ili
ty
 
(2
13
) 
M
itr
of
lo
w
; 
Fr
ee
nd
om
 S
O
LO
 
st
en
tle
ss
; 
Pe
rc
ev
al
 S
 v
al
ve
 
So
rin
 
G
ro
up
 
B
ov
in
e 
pe
ric
ar
di
um
 
tri
-le
af
le
t; 
in
 
ho
ld
er
; v
al
ve
 
N
o 
ce
lls
 
- 
- 
N
o 
- 
16
1;
 4
0;
 
14
3 
A
or
tic
 
18
0;
N
R
.;N
R
. 
Th
e 
va
lv
e 
is
 re
co
m
m
en
de
d 
fo
r p
at
ie
nt
s 7
0 
ye
ar
s a
nd
 
ol
de
r; 
Ex
ce
lle
nt
 h
em
od
yn
am
ic
 p
er
fo
rm
an
ce
, b
ut
 
tra
ns
ie
nt
 th
ro
m
bo
cy
to
pe
ni
a 
w
as
 d
oc
um
en
te
d 
in
 a
ll 
pa
tie
nt
s d
ur
in
g 
ea
rly
 p
os
to
pe
ra
tiv
e 
fo
llo
w
-u
p;
 9
9.
3%
 
ra
te
 o
f s
uc
ce
ss
, 4
,9
%
 o
f m
or
ta
lit
y 
af
te
r 5
 y
ea
rs
, r
ar
e 
co
m
pl
ic
at
io
ns
, n
o 
de
gr
ad
at
io
n 
af
te
r t
he
 fi
rs
t y
ea
r 
(2
10
, 2
14
, 
21
5)
 
E
xp
er
t R
ev
ie
w
s 
in
 M
ol
ec
ul
ar
 M
ed
ic
in
e 
 
 
2 
 
do
i:1
0.
10
17
/e
rm
.2
01
5.
15
 
2 
SA
PI
EN
 3
 
Ed
w
ar
d 
Li
fe
sc
ie
n
ce
, I
nc
. 
St
en
te
d 
ov
in
e 
pe
ric
ar
di
um
 
le
af
le
ts
 w
ith
 
PE
T 
sk
irt
 
no
 c
el
ls
 
- 
- 
N
o 
- 
25
0 
A
or
tic
 
60
 
N
o 
cl
in
ic
al
 d
at
a 
ar
e 
av
ai
la
bl
e 
w
hi
ch
 e
va
lu
at
e 
th
e 
lo
ng
-
te
rm
 im
pa
ct
 
(2
16
) 
Tr
ife
ct
a 
; T
ia
ra
; 
M
od
el
 1
10
00
 
St
. J
ud
e 
M
ed
ic
al
; 
N
eo
va
sc
, 
In
c;
 
Ed
w
ar
ds
 
A
or
tic
 
B
io
pr
os
t. 
B
ov
in
e 
pe
ric
ar
di
al
 
le
af
le
ts
  
N
o 
ce
lls
 
- 
- 
N
o 
- 
75
; 2
; 2
0 
A
or
tic
; 
M
itr
al
; 
A
or
tic
 
N
R
.; 
N
R
.; 
12
 
Im
pr
ov
ed
 h
em
od
yn
am
ic
 p
er
fo
rm
an
ce
 a
cr
os
s a
ll 
va
lv
e 
si
ze
, v
er
y 
lo
w
 p
os
to
pe
ra
tiv
e 
tra
ns
va
lv
ul
ar
 p
re
ss
ur
e;
 N
o 
co
m
pl
ic
at
io
ns
, g
oo
d 
he
m
od
yn
am
ic
 p
er
fo
rm
an
ce
 a
fte
r 
tw
o 
m
on
th
s;
 A
fte
r 1
 y
ea
r, 
go
od
 h
em
od
yn
am
ic
 
pe
rf
or
m
an
ce
 w
ith
ou
t m
aj
or
 c
om
pl
ic
at
io
ns
. 
(2
17
, 9
5,
 
96
) 
Es
po
ir 
PV
; -
 
C
or
lif
e;
 - 
Pu
lm
on
ar
y 
va
lv
e;
 
ho
m
og
ra
ft 
N
o 
ce
lls
 
- 
- 
N
o 
- 
43
; 1
 
Pu
lm
on
ar
y 
72
; 2
4 
U
np
ub
lis
he
d 
re
su
lts
 (S
ta
rte
d 
in
 A
ug
us
t 2
01
4)
. I
n 
30
 
da
ys
, L
V
 fu
nc
tio
n 
w
as
 n
or
m
al
 in
 4
0 
an
d 
m
ild
ly
 
im
pa
ire
d 
in
 3
 p
at
ie
nt
s;
 E
xc
el
le
nt
 m
id
-te
rm
 o
ut
co
m
e,
 
Lo
ng
-te
rm
 fo
llo
w
 u
p 
un
de
r e
va
lu
at
io
n.
 
(2
18
, 9
7)
 
V
en
us
 P
-v
al
ve
 
V
en
us
 
M
ed
Te
ch
, I
nc
. 
Po
rc
in
e 
pe
ric
ar
di
um
 
tri
-le
af
le
t i
n 
se
lf-
ex
pa
nd
in
g 
fr
am
e 
N
o 
ce
lls
 
- 
- 
N
o 
- 
5 
Pu
lm
on
ar
y 
12
; 2
4 
A
fte
r 1
 m
on
th
 o
f f
ol
lo
w
-u
p,
 n
o 
co
m
pl
ic
at
io
ns
 a
nd
 
ex
ce
lle
nt
 v
al
ve
 fu
nc
tio
n.
 R
es
ul
ts
 o
f l
on
g-
te
rm
 st
ud
ie
s 
no
t p
ub
lis
he
d 
ye
t. 
(2
19
) 
 
23
 
24
 
E
xp
er
t R
ev
ie
w
s 
in
 M
ol
ec
ul
ar
 M
ed
ic
in
e 
 
 
3 
 
do
i:1
0.
10
17
/e
rm
.2
01
5.
15
 
3 
T
A
B
L
E
 3
. S
um
m
ar
y 
of
 r
ep
re
se
nt
at
iv
e 
in
 v
itr
o 
st
ud
ie
s i
n 
di
ffe
re
nt
 H
V
T
E
 a
pp
ro
ac
he
s. 
25
 
St
ra
te
gy
 
Sc
af
fo
ld
 
C
el
ls
 
C
ul
tu
re
 
In
 v
iv
o 
st
ud
y 
R
ef
s 
M
at
er
ia
l 
M
an
uf
. 
O
ri
gi
n 
T
yp
e 
D
en
si
ty
 
M
et
ho
d 
D
ay
s 
E
C
M
 
R
es
ul
ts
 
A
rti
f. 
Sy
n.
 
PG
A
-P
LA
 
M
ou
ld
in
g 
an
d 
w
el
di
ng
 
H
um
an
; 
bo
vi
ne
; S
he
ep
 
FB
 o
r 
M
F;
 E
C
 
10
^6
 
ce
ll/
da
y;
 
3x
10
^6
 
ce
lls
 
St
at
ic
 
12
; 1
4 
N
R
. 
So
lid
 sh
ee
ts
 o
f s
of
t a
nd
 fr
ag
ile
 ti
ss
ue
, V
EC
s 
m
on
ol
ay
er
; R
es
em
bl
an
ce
 w
ith
 n
at
iv
e 
tis
su
e,
 
st
ro
ng
er
 a
nd
 st
iff
er
 T
EH
V
 
(1
04
) 
PH
A
; 
PG
A
/P
H
A
/P
4
H
B
 
M
ou
ld
in
g 
or
 sa
lt 
le
ac
hi
ng
 a
nd
 
w
el
di
ng
 
O
vi
ne
 
V
IC
; 
FB
/E
C
/S
M
C
 
(m
ix
) 
2x
10
^6
 
ce
ll/
da
y;
 
8x
10
^6
 
ce
lls
 
St
at
ic
; 
pu
ls
at
ile
 
bi
or
ea
ct
or
 
5;
 8
 
C
ol
la
ge
n 
pr
od
uc
tio
n,
 h
ig
h 
D
N
A
 c
on
te
nt
, 
no
 e
la
st
in
; H
ig
h 
co
lla
ge
n 
co
nt
en
t a
nd
 
ce
llu
la
rit
y 
C
on
flu
en
t V
IC
s o
rie
nt
ed
 w
ith
 th
e 
flo
w
; P
G
A
 
va
lv
es
 w
ith
ou
t c
on
flu
en
t c
el
l l
ay
er
, P
H
A
 a
nd
 
P4
H
B
 v
al
ve
s o
pe
n/
cl
os
e 
sy
nc
hr
on
ou
sl
y 
(R
ef
. 1
05
, 
11
6)
 
PG
A
-P
4H
B
 
(c
oa
tin
g)
 
M
ou
ld
in
g 
an
d 
w
el
di
ng
; N
o 
sc
af
fo
ld
 
H
um
an
; U
C
C
 
B
M
SC
 
5x
10
^6
 
ce
ll/
cm
2 
B
io
re
ac
to
r 
7;
 1
4 
C
ol
la
ge
n 
(2
5%
) a
nd
 G
A
G
 c
on
te
nt
 
(3
7%
) c
om
pa
re
d 
to
 n
at
iv
e 
va
lv
es
, D
N
A
 
co
nt
en
t >
30
0%
 
Sy
nc
hr
on
ou
s l
ea
fle
t o
pe
ni
ng
/c
lo
si
ng
. L
ea
fle
ts
 
co
m
pe
te
nt
 d
ur
in
g 
va
lv
e 
cl
os
ur
e;
 S
at
is
fa
ct
or
y 
te
ns
ile
 st
re
ng
th
, l
es
s d
is
te
ns
ib
ili
ty
 
(1
06
, 2
22
) 
P4
H
B
 ; 
M
e-
H
A
/M
e-
G
el
 
St
er
eo
lit
ho
gr
ap
hy
; 
B
io
pr
in
tin
g 
H
um
an
 
C
D
13
3+
 
U
C
C
; 
V
IC
 
3x
10
^7
; 
5x
10
^6
 
ce
ll/
m
L 
Pu
ls
at
ile
; 
St
at
ic
 
16
 7
 
C
ol
la
ge
n 
(7
7%
), 
El
as
tin
 (6
7%
) a
nd
 
G
A
G
 c
on
te
nt
 (8
5%
) c
om
pa
re
d 
to
 
na
tiv
es
; C
el
ls
 su
rr
ou
nd
ed
 b
y 
EC
M
 a
nd
 
st
ru
ct
ur
e 
m
ai
nt
ai
ne
d 
EC
 la
ye
r f
or
m
at
io
n,
 c
on
ne
ct
iv
e 
tis
su
e 
ob
se
rv
ed
, i
nt
ac
t e
nd
ot
he
lia
l p
he
no
ty
pe
; 
Pr
om
is
in
g 
ap
pr
oa
ch
, r
em
od
el
lin
g 
po
te
nt
ia
l a
nd
 
ac
cu
ra
te
 m
or
ph
ol
og
y 
as
su
re
d 
(2
23
, 1
10
) 
A
rti
f. 
bi
o.
 
B
ov
in
e 
fib
rin
; 
Po
rc
in
e 
co
lla
ge
n 
In
je
ct
io
n-
ca
st
in
g;
 
D
ec
el
lu
la
riz
at
io
n-
m
ou
ld
in
g 
H
um
an
 
N
eo
na
ta
l 
FB
; 
B
M
SC
 
5x
10
^5
 
ce
ll/
m
L;
 
5x
10
^4
 
ce
ll/
cm
2 
St
at
ic
; 
bi
or
ea
ct
or
 
35
; 8
 
C
ol
la
ge
n 
de
te
ct
ed
, c
el
lu
la
rit
y 
co
m
pa
ra
bl
e 
to
 n
at
iv
es
; C
ol
la
ge
n 
fib
re
s 
in
ta
ct
 
C
ap
ab
le
 o
f w
ith
st
an
di
ng
 b
ac
kp
re
ss
ur
e 
an
d 
op
en
ed
-c
lo
se
d 
no
rm
al
 o
pe
ra
tio
n;
 A
fte
r 8
 d
ay
s, 
el
on
ga
te
d 
ce
lls
 a
nd
 g
oo
d 
le
af
le
t a
da
pt
at
io
n.
 
(1
31
, 2
25
) 
D
ec
el
l. 
Po
rc
in
e 
va
lv
e 
D
ec
el
lu
la
riz
at
io
n 
H
um
an
 
EC
; 
N
eo
na
ta
l 
FB
 
10
^5
 
ce
ll/
cm
2;
 
10
^6
 
ce
ll/
da
y 
St
at
ic
 
3;
 5
6 
N
R
.; 
Sy
nt
he
si
s o
f h
um
an
 E
C
M
 
M
on
ol
ay
er
 o
f V
EC
s, 
V
EC
s i
ng
ro
w
th
 n
ot
 
ob
se
rv
ed
; C
el
ls
 v
ia
bl
e,
 4
5%
 re
ce
llu
la
riz
at
io
n 
co
m
pa
re
d 
to
 n
at
iv
e 
va
lv
es
 
(2
20
, 2
21
) 
H
um
an
 v
al
ve
 
D
ec
el
lu
la
riz
at
io
n 
H
um
an
 
EC
; 
H
U
V
EC
 
2x
10
^5
; 
5x
10
^6
 
ce
ll/
cm
2 
B
io
re
ac
to
r 
10
; 2
8 
N
R
.; 
C
ol
la
ge
n 
(8
7%
) a
nd
 e
la
st
in
 (8
5%
) 
co
nt
en
t c
om
pa
re
d 
to
 n
at
iv
e 
va
lv
es
 
V
ia
bl
e 
V
EC
s m
on
ol
ay
er
 w
ith
 h
ig
h 
m
et
ab
ol
ic
 
ac
tiv
ity
; E
C
s m
on
ol
ay
er
 c
re
at
ed
, a
cc
ep
ta
bl
e 
re
si
st
an
ce
 a
nd
 st
ab
ili
ty
 
(9
1,
 1
99
) 
In
 v
iv
o 
TE
 
C
on
ne
ct
iv
e 
tis
su
e 
an
d 
PU
 
R
es
ec
tio
n;
 
sy
nt
he
tic
; 3
D
 
pr
in
te
d 
m
ou
ld
 
R
ab
bi
t; 
G
oa
t 
N
R
. 
N
R
. 
In
 b
od
y 
30
 
C
on
ne
ct
iv
e 
tis
su
e 
co
m
pl
et
el
y 
co
ve
re
d 
N
eo
va
sc
ul
ar
iz
at
io
n,
 o
pe
n/
cl
os
e 
sy
nc
hr
on
iz
at
io
n 
w
ith
 li
ttl
e 
st
en
os
is
 in
 th
e 
va
lv
e 
ro
ot
 a
nd
 lo
w
 re
gu
rg
ita
tio
n 
(2
24
) 
26
 
E
xp
er
t R
ev
ie
w
s 
in
 M
ol
ec
ul
ar
 M
ed
ic
in
e 
 
 
4 
 
do
i:1
0.
10
17
/e
rm
.2
01
5.
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4 
T
A
B
L
E
 4
. S
um
m
ar
y 
of
 p
re
-c
lin
ic
al
 in
ve
st
ig
at
io
ns
 w
ith
 d
iff
er
en
t H
V
T
E
 st
ra
te
gi
es
. 
27
 
St
ra
te
gy
 
Sc
af
fo
ld
 
C
el
ls
 
C
ul
tu
re
 
In
 v
iv
o 
st
ud
y 
R
ef
s 
M
at
er
ia
l 
M
an
uf
. 
O
ri
gi
n 
T
yp
e 
D
en
si
ty
 
M
et
ho
d 
D
ay
s 
M
od
el
 
Po
si
tio
n 
W
ee
ks
 
E
C
M
 
R
es
ul
ts
 
A
rti
f. 
bi
o.
 
O
vi
ne
 
fib
rin
og
en
 
M
ou
ld
in
g 
O
vi
ne
  
M
F;
 
EC
 
10
x1
0^
6 
ce
lls
/c
on
du
it;
 
2x
10
^6
 
ce
ll/
m
L 
B
io
re
ac
to
r 
28
 
Sh
ee
p 
Pu
lm
on
ar
y 
12
 
R
ea
bs
or
pt
io
n 
of
 fi
br
in
 
sc
af
fo
ld
 a
nd
 re
pl
ac
em
en
t 
by
 n
at
ur
al
 E
C
M
 
G
oo
d 
tis
su
e 
de
ve
lo
pm
en
t a
nd
 c
el
l 
di
st
rib
ut
io
n,
 a
ct
iv
e 
re
va
sc
ul
ar
iz
at
io
n.
 
Le
af
le
ts
 in
su
ff
ic
ie
nc
y 
du
e 
to
 ti
ss
ue
 
co
ns
tri
ct
io
n 
(1
32
) 
A
rti
f. 
sy
n.
 
PH
A
 ; 
Po
ly
gl
ac
tin
/
PG
A
; 
PG
LA
/P
G
A
 
M
ou
ld
in
g 
an
d 
w
el
di
ng
 
O
vi
ne
  
EC
; 
FB
; E
C
 
3-
10
x1
0^
6 
ce
lls
 
St
at
ic
 
4;
 1
4 
La
m
b 
Pu
lm
on
ar
y 
17
; 3
; 
11
 
C
ol
la
ge
n 
11
6%
 o
f n
at
iv
e;
 
Le
ss
 d
ev
el
op
ed
; C
ol
la
ge
n,
 
an
d 
el
as
tin
 p
ro
du
ce
d 
Sm
oo
th
 su
rf
ac
es
 a
nd
 n
eo
va
sc
ul
ar
iz
at
io
n 
ob
se
rv
ed
; T
en
si
le
 st
re
ng
th
 si
m
ila
r t
o 
na
tiv
e 
va
lv
es
; E
C
s o
bs
er
ve
d,
 le
ss
 
or
ga
ni
ze
d 
st
ru
ct
ur
e.
 
(1
05
; 1
13
, 
11
4)
 
PG
A
/P
4H
B
 
M
ou
ld
in
g 
an
d 
w
el
di
ng
 
O
vi
ne
; 
B
ab
oo
n 
M
F/
EC
; M
SC
; 
A
FD
C
 
2-
8x
10
^6
 
ce
ll/
cm
2 
B
io
re
ac
to
r; 
D
ire
ct
ly
 
de
liv
er
ed
 
28
; 0
 
La
m
b;
 
B
ab
oo
n 
Pu
lm
on
ar
y 
20
; 4
; 
2,
 1
 
H
ig
he
r E
C
M
 c
on
te
nt
 
(c
ol
la
ge
n,
 G
A
G
s)
 th
an
 
na
tiv
es
; E
C
M
 p
ro
du
ct
io
n;
 
In
cr
ea
se
d 
G
A
G
 c
on
te
nt
; 
EC
M
 re
m
od
el
lin
g 
Sy
nc
hr
on
ou
s l
ea
fle
t o
pe
ni
ng
/c
lo
si
ng
, m
ild
 
to
 m
od
er
at
e 
re
gu
rg
ita
tio
n;
 P
oo
r c
el
l 
su
rv
iv
al
, w
el
l-d
ev
el
op
ed
 E
C
 la
ye
r; 
W
el
l-
co
ns
er
ve
d 
st
ru
ct
ur
es
, c
el
lu
la
r r
em
od
el
lin
g;
 
Po
or
 c
el
l s
ur
vi
va
l, 
ph
ag
oc
yt
ic
 in
fil
tra
tio
n 
(4
, 1
80
; 9
4,
 
19
7)
 
PG
A
/P
LL
A
 
Ex
tru
si
on
 a
nd
 
as
se
m
bl
in
g;
 - 
O
vi
ne
  
B
M
SC
 
10
^9
 ; 
3x
10
^7
 
ce
lls
 
R
ol
le
r 
bo
ttl
e 
28
 
Sh
ee
p 
Pu
lm
on
ar
y 
32
; 2
0 
EC
M
 n
at
ur
al
ly
 d
is
po
se
d;
 
EC
M
 in
cr
ea
si
ng
 w
ith
 
su
rv
iv
al
 ti
m
e 
Sa
tis
fa
ct
or
y 
ce
ll 
di
st
rib
ut
io
n,
 E
C
 la
ye
r 
fo
rm
ed
; A
fte
r 1
2 
w
ee
ks
 a
ni
m
al
s s
ho
w
ed
 
m
od
er
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